Latest filings (excl ownership)
10-K
2023 FY
Annual report
29 Feb 24
8-K
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
28 Feb 24
8-K
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
10 Jan 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
1 Nov 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
8-K
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
1 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
10-Q
2023 Q1
Quarterly report
8 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
8-K
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
1 May 23
PRE 14A
Preliminary proxy
21 Apr 23
10-K
2022 FY
Annual report
1 Mar 23
8-K
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
28 Feb 23
8-K
U.S. Commercial launch expected Q1 2023
28 Dec 22
8-K
TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
10 Nov 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
S-3ASR
Automatic shelf registration
2 Sep 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
8 Aug 22
S-8
Registration of securities for employees
24 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
23 Jun 22
10-Q
2022 Q1
Quarterly report
10 May 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 22
8-K
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
18 Apr 22
10-K
2021 FY
Annual report
1 Mar 22
8-K
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
1 Mar 22
8-K
Other Events
27 Jan 22
8-K
Entry into a Material Definitive Agreement
4 Jan 22
8-K
TG Therapeutics Provides Regulatory Update
30 Nov 21
10-Q
2021 Q3
Quarterly report
8 Nov 21
8-K
TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
4 Nov 21
10-Q
2021 Q2
Quarterly report
6 Aug 21
8-K
TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
2 Aug 21
8-K
Departure of Directors or Certain Officers
23 Jun 21
8-K
Amendments to Articles of Incorporation or Bylaws
21 Jun 21
10-Q
2021 Q1
Quarterly report
10 May 21
8-K
TG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
10 May 21
Latest ownership filings
4
Sagar Lonial
15 Mar 24
4
Laurence N Charney
13 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
5
Sean A Power
14 Feb 24
SC 13G/A
Darwin Global Management, Ltd.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
SC 13G/A
STATE STREET CORP
25 Jan 24
4
Laurence N Charney
8 Jan 24
4
MICHAEL S WEISS
8 Jan 24
4
Sean A Power
5 Jan 24
144
Notice of proposed sale of securities
5 Jan 24
144
Notice of proposed sale of securities
3 Jan 24
4
Sagar Lonial
29 Sep 23
4
Kenneth Hoberman
29 Sep 23
4
Laurence N Charney
29 Sep 23
4
DANIEL HUME
29 Sep 23
4
Yann Echelard
29 Sep 23
4
MICHAEL S WEISS
14 Aug 23
4
Sagar Lonial
26 Jun 23
144
Notice of proposed sale of securities
23 Jun 23
4
Sean A Power
5 Jun 23
144
Notice of proposed sale of securities
2 Jun 23
SC 13G
Darwin Global Management, Ltd.
3 Apr 23
4
Sean A Power
14 Mar 23
4
MICHAEL S WEISS
14 Mar 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
SC 13G/A
STATE STREET CORP
3 Feb 23
SC 13G/A
BlackRock Inc.
1 Feb 23
4
Yann Echelard
6 Jan 23
4
Laurence N Charney
6 Jan 23
SC 13G/A
VANGUARD GROUP INC
11 Oct 22
4
MICHAEL S WEISS
22 Jul 22
4
Sean A Power
22 Jul 22
4
Sagar Lonial
22 Jul 22
4
DANIEL HUME
22 Jul 22
4
Kenneth Hoberman
22 Jul 22
4
Yann Echelard
22 Jul 22